Madrigal Pharmaceuticals stock holds near $531 after fresh analyst data

Published on 09/19/2026 at 20:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal Pharmaceuticals stock traded at $531.52 on September 18, 2026, with a consensus target of $699.64. MarketBeat also showed a market cap of $12.35 billion.

MDGL, US5563691094, Illustration mit AI erstellt.

Madrigal Pharmaceuticals stock (US5563691094) closed at USD 531.52 on September 18, 2026, and MarketBeat put the consensus target at USD 699.64, implying 31.63 percent upside from that snapshot.

Analyst gap stays wide

On September 19, 2026, MarketBeat also showed a market cap of USD 12.35 billion for Madrigal Pharmaceuticals, while the same data set listed an extended-hours quote of USD 531.48 after the regular close.

The same snapshot put the stock below the consensus target by USD 168.12 per share, a gap that matters more than a one-day move for investors watching the re-rating case.

Biotech and MASH angle

Simply Wall St described Madrigal Pharmaceuticals on September 19, 2026, as a biopharmaceutical company focused on novel therapeutics for metabolic dysfunction-associated steatohepatitis in the United States.

That business mix leaves the stock tied to clinical and commercial execution, so the market cap of USD 12.35 billion and the USD 531.52 close frame the current valuation debate more clearly than broad sector labels.

Stock near the target

Madrigal Pharmaceuticals stock finished at USD 531.52 on September 18, 2026, with extended trading at USD 531.48 later that day. The chart still leaves it well below the USD 699.64 consensus target from MarketBeat.